Molecular Pathology Team, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK.
Breast Cancer Res. 2009;11 Suppl 3(Suppl 3):S12. doi: 10.1186/bcr2431. Epub 2009 Dec 18.
Next-generation sequencing (also known as massively parallel sequencing) technologies are revolutionising our ability to characterise cancers at the genomic, transcriptomic and epigenetic levels. Cataloguing all mutations, copy number aberrations and somatic rearrangements in an entire cancer genome at base pair resolution can now be performed in a matter of weeks. Furthermore, massively parallel sequencing can be used as a means for unbiased transcriptomic analysis of mRNAs, small RNAs and noncoding RNAs, genome-wide methylation assays and high-throughput chromatin immunoprecipitation assays. Here, I discuss the potential impact of this technology on breast cancer research and the challenges that come with this technological breakthrough.
下一代测序（也称为大规模平行测序）技术正在彻底改变我们在基因组、转录组和表观基因组水平上描述癌症的能力。现在，我们可以在数周内以碱基对分辨率对整个癌症基因组中的所有突变、拷贝数异常和体细胞重排进行编目。此外，大规模平行测序可用于对 mRNA、小 RNA 和非编码 RNA 进行无偏转录组分析、进行全基因组甲基化测定和高通量染色质免疫沉淀测定。在这里，我将讨论这项技术对乳腺癌研究的潜在影响，以及这项技术突破所带来的挑战。
